BCX17725

DRUG2 trials

Sponsors

Biocryst Pharmaceuticals Inc., BioCryst Pharmaceuticals

Conditions

Netherton Syndrome

Phase 1

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

RecruitingNCT06539507

BioCryst PharmaceuticalsNetherton Syndrome

Start: 2024-09-26End: 2026-12-01Target: 78Updated: 2026-08-27

A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME

Not yet recruitingCTIS2025-521973-16-00

Biocryst Pharmaceuticals Inc.Netherton Syndrome

Target: 6Updated: 2026-01-23